



June 19, 2014

New C1™ Open App™ Program

Program enables researchers to develop new single-cell applications on the C1™ Single-Cell Auto Prep

Fluidigm Accelerates Single-Cell Science with the New C1™ Open App™ Program

Program enables researchers to develop new single-cell applications on the C1™ Single-Cell Auto Prep System

SOUTH SAN FRANCISCO, Calif., June 19, 2014 — Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the C1™ Open App™ Program, giving researchers the ability to create and share new single-cell applications on the C1 Single-Cell Auto Prep System.

The C1 system is a powerful and easy-to-use platform that allows researchers to explore cellular heterogeneity across a wide range of single-cell applications. With one integrated workflow, researchers can isolate, stain, lyse, and process 96 live viable cells in less than 24 hours. Now the scientific community can take advantage of the powerful capability of the C1 system and the innovative C1 integrated fluidic circuit (IFC) architecture to modify or develop new scripts.

"Opening the C1 system to custom scripts is a major strategic initiative for Fluidigm. It allows our users to quickly expand the platform into new areas of research, such as epigenetics and protein detection, as well as implement alternate whole transcriptome techniques," said Candia Brown, Fluidigm's Director, Product Marketing, Single-Cell Genomics. "With the rapid adoption of the C1 system and its continued use by the scientific community, this program will scale its capabilities dramatically," Brown added.

Two key elements of this new Open App Program are the C1 Script Builder software (available now) and the C1 Script Hub (expected to be available in late 2014).

The C1 Script Builder is a standalone desktop software with which users can create custom scripts for their C1 Open App IFC and import them to their C1 system to run their script. Fluidigm provides STA, mRNA Seq, and DNA Seq script templates where customers can modify reagent incubation temperatures and duration (single temperature or multiple temperature steps), and the software validates the entire script workflow and estimates script lengths. Customers will be able to evaluate alternate cell loading and lysing methods, develop new staining protocols, and evaluate alternate enzymes. Using the C1 Script Builder, customers can produce multiple-step and multiple-script protocols, extend cell loading times, set loading temperatures, and set multi-step incubation times and temperatures.

The C1 Script Hub is a web portal through which Fluidigm will make third-party protocols available to the C1 user base. C1 Script Builder customers will be able to publish their protocols through the web portal (scripts + worksheet) for other C1 users to download, install, and use on their C1 systems. The C1 Script Hub is expected to be available in late 2014.

USE OF FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the launch of new Fluidigm products and applications and Fluidigm's product and marketing plans, development, objectives, expectations and/or strategies. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, launching, marketing, and selling new products and applications. Information on these and additional risks affecting Fluidigm's business and operating results are contained in its filings with the Securities and Exchange Commission, including its most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements except as may be required by law.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories,

and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

For more information, please visit: <http://www.fluidigm.com>.

Fluidigm, the Fluidigm logo, C1 and Open App are trademarks or registered trademarks of Fluidigm Corporation.
Contact

Michaeline Bunting
Senior Director, Marketing
Fluidigm Corporation
650 737 4190
michaeline.bunting@fluidigm.com